Signs and symptoms of cancer

Last updated
Cancer signs and symptoms
Symptoms of cancer metastasis.svg
Symptoms of cancer can be based on the affected organs
Specialty Oncology
Deaths8.8 million (2015) [1]

Cancer symptoms are changes in the body caused by the presence of cancer. They are usually caused by the effect of a cancer on the part of the body where it is growing, although the disease can cause more general symptoms such as weight loss or tiredness. There are more than 100 different types of cancer with a wide range of signs and symptoms which can manifest in different ways. [2]

Contents

Signs and Symptoms

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. [3] [4] Cancer can be difficult to diagnose because its signs and symptoms are often nonspecific, meaning they may be general phenomena that do not point directly to a specific disease process. [5]

In medicine, a sign is an objective piece of data that can be measured or observed, as in a high body temperature (fever), a rash, or a bruise. [6] A symptom, by contrast, is the subjective experience that may signify a disease, illness or injury, such as pain, dizziness, or fatigue. [7] Signs and symptoms are not mutually exclusive, for example a subjective feeling of fever can be noted as sign by using a thermometer that registers a high reading. [7]

Because many symptoms of cancer are gradual in onset and general in nature, cancer screening (also called cancer surveillance) is a key public health priority. This may include laboratory work, physical examinations, tissue samples, or diagnostic imaging tests that a community of experts recommends be conducted at set intervals for particular populations. Screenings can identify cancers before symptoms develop, or early in the disease course. [8] Certain cancers can be prevented with vaccines against the viruses that cause them (e.g., HPV vaccines as prevention against cervical cancer). [9]

Additionally, patient education about worrisome symptoms that require further evaluation is paramount to reduce morbidity and mortality from cancer. Symptoms that cause excess worry, symptoms that persist or are unexplained, and/or the appearance of several symptoms together particularly warrant evaluation by a health professional.[ citation needed ]

Mechanisms

Cancer may produce symptoms in one or more of the following ways:[ citation needed ]

Suspicious Symptoms

Symptoms of cancer may be nonspecific changes to the individual's sense of physical well-being (constitutional symptoms), or may localize to a particular organ system or anatomic region.[ citation needed ]

The following symptoms may be manifestations of an underlying cancer. [12] [13] [14] Alternatively, they may point to non-cancerous disease processes, benign tumors, or even be within the physiological range of normal. They may appear at the primary site of cancer or be symptoms of cancer metastasis, or spread. Further workup by a trained healthcare professional is required to diagnose cancer. [13]

Constitutional Symptoms

  • Unexplained weight loss: Weight loss that is unintended and not explained by diet, exercise or other illness may be a warning sign of many types of cancer
  • Unexplained pain: Pain that persists, has no clear cause, and does not respond to treatment may be a warning sign of many types of cancers.
  • Unexplained tiredness or fatigue: Unusual and persistent tiredness may point to underlying illness, including blood cell cancers like leukemia or lymphoma
  • Unexplained night sweats or fever: These may be signs of an immune system cancer. Fever in children rarely points to malignancy, but may merit evaluation.

Local Symptoms

SystemSymptomCancer TypeNotes
Head & NeckDifficulty in swallowingEsophageal (throat) or GI cancer
Respiratorypersistent cough or hoarseness

Blood in sputum (hemoptysis)

Shortness of breath (dyspnea)

Lung cancer
Gastrointestinal (GI)Change in bowel habits

Unusual diarrhea or constipation

Continuing indigestion or heartburn

Abdominal pain, bloating, or nausea

Blood in the stool

Enlarged liver

GI or GU cancers, including stomach, pancreatic, colon, prostate or bladderSignificant bloating or the feeling of fullness (satiety) is a known symptom of ovarian or uterine cancers.
Genitourinary (GU)Difficulty passing urine

Any abnormal bleeding, including menstrual irregularities*, bleeding from the vagina

blood in urine

Urothelial cancers, as in bladder or kidney cancer or GI cancers

Uterine, ovarian or vaginal cancer

*Postmenopausal vaginal bleeding is always abnormal and should be evaluated for possible cancer.
Skin/MucosaPersistent sore or ulcer*

Unexplained rash

Unusual lump

Changes in a mole*

Skin cancers, including melanoma, basal cell carcinoma, or squamous cell carcinoma

Oral cancers, or other cancers of the tissues where they develop

*These are increasingly concerning in people who use tobacco or alcohol.

**These are often evaluated with the ABCD mnemonic for changes in

BreastNew lumps

Changes in skin texture, e.g. dimpling

Inversion of nipples

Unusual or bloody discharge

Breast CancerBreast cancer develops especially but not exclusively in women.
MusculoskeletalBone pain

Fractures, esp. spinal

Hematologic/ImmunologicExcessive bruising or bleeding

Swollen lymph node or unusual lump

Leukemias

Lymphomas

Bruises out of proportion to direct injury or
NeurologicPersistent headaches

New-onset seizures

Vertigo

Brain cancerHeadaches that last for more than two weeks, or a first presentation of seizure should warrant evaluation for possible brain tumor.

Medical Workup

When patients present with "suspicious symptoms", healthcare providers follow specific guidelines or diagnostic pathways to evaluate for potential cancer. Healthcare professionals face challenges of distinguishing potentially serious symptoms as opposed to common benign conditions. Recent research in the UK has shown that some cancer types often require multiple consultations before confirmed diagnosis. Understanding these diagnostic challenges is crucial for both the healthcare providers and patients in navigating the cancer diagnostic process effectively and ethically. [15]

A healthcare professional may pursue a formal diagnostic workup to evaluate symptoms of cancer. The tests ordered will depend upon the type of cancer suspected. These may include the following: [16]

Early Detection Technologies

Modern approaches to cancer detection have evolved beyond traditional symptom recognition because of new technologies that can potentially identify cancers at earlier, more treatable stages.

Biomarkers

Cancer biomarkers provide crucial information about the different states of cells when transitioning from healthy to malignant cancer conditions. Recent research has shown proof of extensive biomarker technologies that show potential for early cancer detection, primarily focusing on minimally invasive approaches. These minimally invasive approaches are being developed to complement traditional screening methods. Essentially, these modern technologies and how they can detect cancer at earlier stages rather than traditional symptom recognition, could overall potentially improve survival rates. [17]

Liquid Biopsies

Liquid biopsies allow for minimally invasive molecular characterizations of cancers through the detection of circulating different cells and their DNA.  This technology offers guidance on how these approaches could be beneficial for detection of early cancer symptoms before they actually develop, potentially leading to earlier intervention and improved outcomes. [18]

Artificial Intelligence (AI)

Artificial intelligence (AI) applications in cancer diagnosis across clinical practices, while also keeping in mind the potential challenges, could be a beneficial impact for cancer screening and diagnostic processes. AI algorithms can analyze medical images, detect patterns in biomarker data, and help identify patients who are high-risk and may benefit from more extensive screening and applications like ai. These technologies could aim to assist healthcare professionals in screening asymptomatic patients, investigating symptomatic patients, and diagnosing cancer more effectively than just traditional methods alone. [19]

Cancers treatments may include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy (including immunotherapy such as monoclonal antibody therapy) and synthetic lethality, most commonly as a series of separate treatments (e.g. chemotherapy before surgery). Some of these cancer therapies may produce treatment-related, or secondary, symptoms, including:

Symptoms that require immediate treatment include:

Cancer-related symptom burden refers to the cumulative impact of physical, psychological, and emotional symptoms—such as pain, fatigue, nausea, and emotional distress (e.g., anxiety, depression)—experienced by individuals with cancer due to the disease and its treatment. This burden encompasses both the severity of these symptoms and the patient's perception of their impact on daily life and overall well-being. [22]

In 2013, the Eastern Cooperative Oncology Group (ECOG), informed by recommendations from an expert panel from the Center for Medical Technology Policy and comprehensive systematic reviews, established core symptoms that represent commonly reported cancer-related (including treatment-related) symptoms for the purposes of clinical research and assessment of quality of care. [23] [24] [25] [26] Individuals with breast, prostate, colorectal, and lung cancers—of all disease stages and phases of care—were represented in their large multi-center study. These symptoms include, but are not limited to:

Other patient-reported outcomes such health-related quality of life (HRQoL), a broader construct which subjectively assesses life as a whole, may be confused with cancer-related symptom burden. Both constructs are considered when effectively defining endpoints in cancer clinical trials that share a common goal of symptom reduction. [22] Contrary to HRQoL, cancer-related symptom burden focuses more on the impact of nonspecific, often co-occurring symptoms, and symptom clustering which are not are not monitored as closely as other toxicities within clinical settings, to ultimately inform symptom management. [22]

Measures that assess for cancer-related symptom burden recognize that patients can experience multiple symptoms as a result of disease and/or treatment. Collectively, they can be thought of as an indicators of symptom severity and the perception of the extent to which these symptoms affect daily functioning. [22]

Screening and Assessment

A variety of PROs are utilized to assess symptom burden among cancer patients participating in cancer clinical research. Common measures recommended due to their psychometric properties and utility in cancer clinical research include:

Many of these measures also have adapted versions according to specific cancer and/or illness type. [24] In addition to clinical trials, many PROs are increasingly being collected within ambulatory care settings to inform symptom management and intervention as well as through electronic methods such as electronic patient-reported outcomes.

Diagnosis

There is no formal diagnosis for cancer-related symptom burden as it is conceptualized as a constellation of concerns commonly reported by individuals with cancer, any of which, may be endorsed at any time before, during, or after treatment and throughout the cancer control continuum. [27]

Accurate assessment of cancer-related symptom burden requires repeatedly measuring the types, severity, and effects symptoms that patients experience throughout their cancer journey. Scientific review studies have advocated for standardization among PROs to capture this information in a consistent manner. [28] [29] [23] [24] Existing measures allow clinicians to measure the severity of symptoms and follow their progression over time to ensure timely interventions can be made to minimize any negative patient impacts.

Further, scientific reviews have identified common clusters of symptoms in cancer patients such as fatigue, pain, and depression. Identification of such clusters is important since they can contribute to increased symptom burden and negatively impact quality of life. [30] Holistic diagnostic methods that recognize the interactions between several symptoms are important to appropriately diagnosing and treating these symptoms. [30] Standardized PROs along with identification of common symptom clusters can help provide clinicians with the necessary information to manage symptom burden in a timely manner, thereby improving patient care and outcomes. [30]

Current Interventions

Recent research on ePROs have provided general support for the implementation of ePRO-based interventions to improve symptom burden, quality of life, and survival among individuals with cancer. [31] Additionally, among patients receiving specific treatments, these interventions were found to be effective in reducing symptom burden and promoting better quality of life. [31]

A scientific review also highlighted potential non-pharmacological interventions for individuals with cancer experiencing pain concerns and facing social disparities such as identifying as an ethnic minority, having low income, and vulnerable women. [32] This study revealed a high risk of bias across studies evaluating education, coaching, and online support group interventions and underscored the need to further investigate supportive care interventions that are responsive to the needs of individuals facial social disparities. [32]

Another review of randomized controlled trials evaluating nursing interventions aimed at reducing symptom burden in adult cancer patients highlighted some clinically meaningful reductions in symptom burden but cautioned against making any definitive conclusions and potential generalizations regarding key components, circumstances, and target population of the interventions and called for further research. [33]

There is also some support for the potential utility of mindfulness based interventions (MBIs) in reducing symptom burden among individuals with cancer. [34]

Prognosis

Comprehensive review studies demonstrate that symptom burden can often persist beyond completion of primary treatment. A meta-analysis that included breast, gynecological, prostate, and colorectal cancer survivors showed that fatigue, pain, and psychological distress persisted well beyond treatment completion, ultimately impacting quality of life negatively. [35] This in turn, highlights the need for continued symptom monitoring, management, and supportive care that is responsive to the long-term needs of cancer survivors. [35]

Additionally, studies suggest that cancer patients with advanced disease often have several different co-occurring symptoms, which translates into a high overall burden. One scientific review revealed that pain, fatigue, and depression symptoms overlapped in a way that negatively impacted daily functioning and quality of life in these patients. [30] Understanding and treating these symptom clusters from a holistic palliative care perspective is critical to patients' outcomes and quality of life. [30]

The general increase observed in both symptom burden and HRQoL in late stage vs. early stage disease across 10 cancer types studied in a recent scientific review, also underscores the need for earlier detection and intervention to promote survival as well as minimize the adverse effects on symptom burden and HRQoL. [36]

These findings underscore the need for comprehensive, ongoing symptom assessment and treatment across the cancer control continuum [27] to improve cancer patient outcomes and reduce symptom burden.

Socio-cultural Considerations

Recent research has revealed that cancer-related symptom burden varies widely by race and ethnicity. For example, a retrospective analysis of symptom burden by race and ethnicity in a large cohort of cancer patients revealed that racial and ethnic minority patients experienced greater symptom burden than non-Hispanic White patients. [37]

Additionally, studies on social determinants of health and symptom burden in cancer treatment suggest that marginalized cancer survivors might experience significantly greater symptom burden including higher frequency and severity, and higher levels of depression and anxiety. [38] Supporting this notion, findings from a review that examined quality of life among U.S. Latino cancer survivors revealed that compared to other racial/ethnic communities, Hispanic/Latinos reported higher symptom burden across several HRQoL domains. [39] Further, there is some evidence to suggest a disparity in the reporting of symptom burden within routine cancer care among individuals who identify as Black. [37]

Overall research on potential symptom burden disparities among individuals with cancer from historically-marginalized populations is currently limited. Another recent review that examined cognitive impairment among Black, Hispanic, and Asian breast cancer survivors from the U.S. revealed that Black and Hispanic patients were more likely to report cognitive impairment concerns relative to White patients, pre and post chemotherapy. [40] Additionally, Black cancer survivors reported greater cognitive concerns when compared to their White counterparts. [40]

References

  1. Wang, Haidong; et al. (8 October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC   5388903 . PMID   27733281.
  2. "What is Cancer?". Cancer.Net. 2012-08-01. Retrieved 2021-12-09.
  3. World Health Organization (12 September 2018). "Cancer". Cancer: Fact Sheet. Archived from the original on 2018-04-28. Retrieved 29 November 2021.
  4. National Cancer Institute (17 September 2007). "What is Cancer?". National Institutes of Health. Archived from the original on 2016-05-28. Retrieved 29 November 2021.
  5. Jørgensen, Sara Falk; Ravn, Pernille; Thorsen, Søren; Worm, Signe Westring (2017-12-02). "Characteristics and outcome in patients with non-specific symptoms and signs of cancer referred to a fast track cancer patient pathway; a retrospective cohort study". BMC Cancer. 17 (1): 809. doi: 10.1186/s12885-017-3826-z . ISSN   1471-2407. PMC   5712161 . PMID   29197366.
  6. Merriam Webster. "Sign (medical definition)". Merriam Webster.Com. Archived from the original on 2006-05-20. Retrieved 29 November 2021.
  7. 1 2 Marie T. O'Toole, ed. (2013). Mosby's medical dictionary (9th ed.). St. Louis, MO: Elsevier/Mosby. ISBN   978-0-323-08541-0. OCLC   788298656.
  8. "Cancer Screening Overview (PDQ®)–Patient Version - National Cancer Institute". www.cancer.gov. 2010-01-13. Retrieved 2021-11-30.
  9. "How Cancer is Treated". Cancer.Net. 2008-03-18. Retrieved 2021-11-30.
  10. Grimes, David Robert; O'Riordan, Elizabeth (2023-11-01). "Starving cancer and other dangerous dietary misconceptions" . The Lancet Oncology. 24 (11): 1177–1178. doi:10.1016/S1470-2045(23)00483-7. ISSN   1470-2045. PMID   37922928.
  11. Horsted, Freesia; West, Joe; Grainge, Matthew J. (2012-07-31). "Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis". PLOS Medicine. 9 (7): e1001275. doi: 10.1371/journal.pmed.1001275 . ISSN   1549-1676. PMC   3409130 . PMID   22859911.
  12. "17 Cancer Symptoms You Shouldn't Ignore". ucsfhealth.org. Retrieved 2021-11-30.
  13. 1 2 "Signs and symptoms of cancer". Cancer Research UK. 2015-03-17. Retrieved 2021-11-30.
  14. "Signs and Symptoms of Cancer | Do I Have Cancer?". www.cancer.org. Retrieved 2021-11-30.
  15. Hamilton, William (2010-02-01). "Cancer diagnosis in primary care". British Journal of General Practice. 60 (571): 121–128. doi:10.3399/bjgp10X483175. ISSN   0960-1643. PMC   2814263 . PMID   20132704.
  16. "Tests and Procedures". Cancer.Net. 2010-07-24. Retrieved 2021-11-30.
  17. Prasanth, B. Krishna; Alkhowaiter, Saad; Sawarkar, Gaurav; Dharshini, B. Divya; R Baskaran, Ajay (December 2023). "Unlocking Early Cancer Detection: Exploring Biomarkers, Circulating DNA, and Innovative Technological Approaches". Cureus. 15 (12): e51090. doi: 10.7759/cureus.51090 . ISSN   2168-8184. PMC   10808885 . PMID   38274938.
  18. Batool, Syeda Maheen; Yekula, Anudeep; Khanna, Prerna; Hsia, Tiffaney; Gamblin, Austin S.; Ekanayake, Emil; Escobedo, Ana K.; You, Dong Gil; Castro, Cesar M.; Im, Hyungsoon; Kilic, Tugba; Garlin, Michelle Andrea; Skog, Johan; Dinulescu, Daniela M.; Dudley, Jonathan (2023-10-17). "The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring". Cell Reports. Medicine. 4 (10): 101198. doi:10.1016/j.xcrm.2023.101198. ISSN   2666-3791. PMC   10591039 . PMID   37716353.
  19. Hunter, Benjamin; Hindocha, Sumeet; Lee, Richard W. (2022-03-16). "The Role of Artificial Intelligence in Early Cancer Diagnosis". Cancers. 14 (6): 1524. doi: 10.3390/cancers14061524 . ISSN   2072-6694. PMC   8946688 . PMID   35326674.
  20. Magdi Hanna; Zbigniew Zylicz, eds. (2013). Cancer pain. London: Springer. ISBN   978-0-85729-230-8. OCLC   855544999.
  21. Millard, Samantha K.; de Knegt, Nanda C. (December 2019). "Cancer Pain in People With Intellectual Disabilities: Systematic Review and Survey of Health Care Professionals". Journal of Pain and Symptom Management. 58 (6): 1081–1099.e3. doi: 10.1016/j.jpainsymman.2019.07.013 . ISSN   1873-6513. PMID   31326504. S2CID   198136476.
  22. 1 2 3 4 Cleeland, C. S. (2007-10-01). "Symptom Burden: Multiple Symptoms and Their Impact as Patient-Reported Outcomes". JNCI Monographs. 2007 (37): 16–21. doi:10.1093/jncimonographs/lgm005. ISSN   1052-6773. PMID   17951226.
  23. 1 2 Cleeland, Charles S.; Zhao, Fengmin; Chang, Victor T.; Sloan, Jeff A.; O'Mara, Ann M.; Gilman, Paul B.; Weiss, Matthias; Mendoza, Tito R.; Lee, Ju-Whei; Fisch, Michael J. (2013). "The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study". Cancer. 119 (24): 4333–4340. doi:10.1002/cncr.28376. ISSN   1097-0142. PMC   3860266 . PMID   24114037.
  24. 1 2 3 Basch, Ethan; Abernethy, Amy P.; Mullins, C. Daniel; Reeve, Bryce B.; Smith, Mary Lou; Coons, Stephen Joel; Sloan, Jeff; Wenzel, Keith; Chauhan, Cynthia; Eppard, Wayland; Frank, Elizabeth S.; Lipscomb, Joseph; Raymond, Stephen A.; Spencer, Merianne; Tunis, Sean (December 2012). "Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult Oncology" . Journal of Clinical Oncology. 30 (34): 4249–4255. doi:10.1200/JCO.2012.42.5967. ISSN   0732-183X. PMID   23071244.
  25. Kim, Jung-Eun Esther; Dodd, Marylin J.; Aouizerat, Bradley E.; Jahan, Thierry; Miaskowski, Christine (2009-04-01). "A Review of the Prevalence and Impact of Multiple Symptoms in Oncology Patients". Journal of Pain and Symptom Management. 37 (4): 715–736. doi:10.1016/j.jpainsymman.2008.04.018. ISSN   0885-3924. PMC   2688644 . PMID   19019626.
  26. Reilly, Carolyn Miller; Bruner, Deborah Watkins; Mitchell, Sandra A.; Minasian, Lori M.; Basch, Ethan; Dueck, Amylou C.; Cella, David; Reeve, Bryce B. (2013-06-01). "A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment". Supportive Care in Cancer. 21 (6): 1525–1550. doi:10.1007/s00520-012-1688-0. ISSN   1433-7339. PMC   4299699 . PMID   23314601.
  27. 1 2 "Cancer Control Continuum | Division of Cancer Control and Population Sciences (DCCPS)". cancercontrol.cancer.gov.
  28. Qdaisat, Aiham; Stroh, Elizabeth; Reyes-Gibby, Cielito; Wattana, Monica K.; Viets-Upchurch, Jayne; Li, Ziyi; Page, Valda D.; Fatima, Huda; Chaftari, Patrick; Elsayem, Ahmed (January 2024). "Severity of Symptoms as an Independent Predictor of Poor Outcomes in Patients with Advanced Cancer Presenting to the Emergency Department: Secondary Analysis of a Prospective Randomized Study". Cancers. 16 (23): 3988. doi: 10.3390/cancers16233988 . ISSN   2072-6694. PMC   11640218 . PMID   39682175.
  29. Howell, Kristen E.; Baedke, Jessica L.; Bagherzadeh, Farideh; McDonald, Aaron; Nathan, Paul C.; Ness, Kirsten K.; Hudson, Melissa M.; Armstrong, Gregory T.; Yasui, Yutaka; Huang, I.-Chan (January 2024). "Using mHealth Technology to Evaluate Daily Symptom Burden among Adult Survivors of Childhood Cancer: A Feasibility Study". Cancers. 16 (17): 2984. doi: 10.3390/cancers16172984 . ISSN   2072-6694. PMC   11394214 . PMID   39272842.
  30. 1 2 3 4 5 Dong, Skye Tian; Butow, Phyllis N.; Costa, Daniel S.J.; Lovell, Melanie R.; Agar, Meera (September 2014). "Symptom Clusters in Patients With Advanced Cancer: A Systematic Review of Observational Studies" . Journal of Pain and Symptom Management. 48 (3): 411–450. doi: 10.1016/j.jpainsymman.2013.10.027 . PMID   24703941.
  31. 1 2 Li, Yunhuan; Li, Juejin; Hu, Xiaolin (2023-11-01). "The effectiveness of symptom management interventions based on electronic patient-reported outcomes (ePROs) for symptom burden, quality of life, and overall survival among patients with cancer: A meta-analysis of randomized controlled trials" . International Journal of Nursing Studies. 147: 104588. doi:10.1016/j.ijnurstu.2023.104588. ISSN   0020-7489. PMID   37690275.
  32. 1 2 Santos Salas, Anna; Fuentes Contreras, Jorge; Armijo-Olivo, Susan; Saltaji, Humam; Watanabe, Sharon; Chambers, Thane; Walter, Lori; Cummings, Greta G. (2016-02-01). "Non-pharmacological cancer pain interventions in populations with social disparities: a systematic review and meta-analysis" . Supportive Care in Cancer. 24 (2): 985–1000. doi:10.1007/s00520-015-2998-9. ISSN   1433-7339. PMID   26556211.
  33. Coolbrandt, Annemarie; Wildiers, Hans; Aertgeerts, Bert; Van der Elst, Elisa; Laenen, Annouschka; Dierckx de Casterlé, Bernadette; van Achterberg, Theo; Milisen, Koen (2014-03-01). "Characteristics and effectiveness of complex nursing interventions aimed at reducing symptom burden in adult patients treated with chemotherapy: A systematic review of randomized controlled trials" . International Journal of Nursing Studies. 51 (3): 495–510. doi:10.1016/j.ijnurstu.2013.08.008. ISSN   0020-7489. PMID   24074939.
  34. Rouleau, Codie R.; Garland, Sheila N.; Carlson, Linda E. (2015-06-01). "The impact of mindfulness-based interventions on symptom burden, positive psychological outcomes, and biomarkers in cancer patients". Cancer Management and Research. 7: 121–131. doi: 10.2147/CMAR.S64165 . PMC   4457221 . PMID   26064068.
  35. 1 2 Harrington, Cherise B.; Hansen, Jennifer A.; Moskowitz, Michal; Todd, Briana L.; Feuerstein, Michael (June 2010). "It's Not over When it's Over: Long-Term Symptoms in Cancer Survivors—A Systematic Review" . The International Journal of Psychiatry in Medicine. 40 (2): 163–181. doi:10.2190/PM.40.2.c. ISSN   0091-2174. PMID   20848873.
  36. Chung, Karen C.; Muthutantri, Anushini; Goldsmith, Grace G.; Watts, Megan R.; Brown, Audrey E.; Patrick, Donald L. (2024-07-22). "Symptom impact and health-related quality of life (HRQoL) assessment by cancer stage: a narrative literature review". BMC Cancer. 24 (1): 884. doi: 10.1186/s12885-024-12612-z . ISSN   1471-2407. PMC   11265440 . PMID   39039461.
  37. 1 2 Bulls, Hailey W.; Chang, Pi-Hua; Brownstein, Naomi C.; Zhou, Jun-Min; Hoogland, Aasha I.; Gonzalez, Brian D.; Johnstone, Peter; Jim, Heather S. L. (March 2022). "Patient-reported symptom burden in routine oncology care: Examining racial and ethnic disparities". Cancer Reports. 5 (3): e1478. doi:10.1002/cnr2.1478. ISSN   2573-8348. PMC   8955049 . PMID   34165256.
  38. Badger, Terry A.; Segrin, Chris; Crane, Tracy E.; Chalasani, Pavani; Arslan, Waqas; Hadeed, Mary; Sikorskii, Alla (March 2023). "Social Determinants of Health and Symptom Burden During Cancer Treatment". Nursing Research. 72 (2): 103–113. doi:10.1097/NNR.0000000000000636. ISSN   1538-9847. PMC   9991997 . PMID   36729777.
  39. Samuel, Cleo A.; Mbah, Olive M.; Elkins, Wendi; Pinheiro, Laura C.; Szymeczek, Mary Anne; Padilla, Neda; Walker, Jennifer S.; Corbie-Smith, Giselle (2020-10-01). "Calidad de Vida: a systematic review of quality of life in Latino cancer survivors in the USA". Quality of Life Research. 29 (10): 2615–2630. doi:10.1007/s11136-020-02527-0. ISSN   1573-2649. PMC   8285081 . PMID   32430782.
  40. 1 2 Dunovan, Shanon G.; Zak, Roksana; Lally, Robin M. (2022-10-19). "Illuminating Black, Hispanic, and Asian Women's Breast Cancer-related Cognitive Impairment Symptom Experience: An Integrative Review". Cancer Care Research Online. 2 (4): e030. doi: 10.1097/CR9.0000000000000030 . ISSN   2691-3623.